OTC intron 4 variations mediate pathogenic splicing patterns caused by the c.386G>A mutation in humans and spfash mice, and govern susceptibility to RNA-based therapies
Tóm tắt
Aberrant splicing is a common outcome in the presence of exonic or intronic variants that might hamper the intricate network of interactions defining an exon in a specific gene context. Therefore, the evaluation of the functional, and potentially pathological, role of nucleotide changes remains one of the major challenges in the modern genomic era. This aspect has also to be taken into account during the pre-clinical evaluation of innovative therapeutic approaches in animal models of human diseases. This is of particular relevance when developing therapeutics acting on splicing, an intriguing and expanding research area for several disorders. Here, we addressed
Creation and co-expression of engineered U1snRNAs with human and mouse minigenes, either wild-type or harbouring different nucleotide changes, in human (HepG2) and mouse (Hepa1-6) hepatoma cells followed by analysis of splicing pattern. RNA pulldown studies to evaluate binding of specific splicing factors.
Comparative nucleotide analysis suggested a role for the intronic +10-11 nucleotides, and pull-down assays showed that they confer preferential binding to the TIA1 splicing factor in the mouse context, where TIA1 overexpression further increases correct splicing. Consistently, the splicing profile of the human minigene with mouse +10-11 nucleotides overlapped that of mouse minigene, and restored responsiveness to TIA1 overexpression and to compensatory U1snRNA. Swapping the human +10-11 nucleotides into the mouse context had opposite effects.
Moreover, the interplay between the authentic and the adjacent cryptic 5′ss in the human OTC dictates pathogenic mechanisms of several OTCD-causing 5′ss mutations, and only the c.386+5G>A change, abrogating the cryptic 5′ss, was rescuable by engineered U1snRNA.
Subtle intronic variations explain species-specific
Từ khóa
Tài liệu tham khảo
Balestra D, Faella A, Margaritis P, Cavallari N, Pagani F, Bernardi F, et al. An engineered U1 small nuclear RNA rescues splicing-defective coagulation F7 gene expression in mice. J Thromb Haemost. 2014;12(2):177–85.
Balestra D, Barbon E, Scalet D, Cavallari N, Perrone D, Zanibellato S, et al. Regulation of a strong F9 cryptic 5′ss by intrinsic elements and by combination of tailored U1snRNAs with antisense oligonucleotides. Hum Mol Genet. 2015;24(17):4809–16.
Balestra D, Scalet D, Pagani F, Rogalska ME, Mari R, Bernardi F, et al. An exon-specific U1snRNA induces a robust factor IX activity in mice expressing multiple human FIX splicing mutants. Mol Ther Nucleic Acids. 2016;5(10):e370.
Balestra D, Giorgio D, Bizzotto M, Fazzari M, Ben Zeev B, Pinotti M, et al. Splicing mutations impairing CDKL5 expression and activity can be efficiently rescued by U1snRNA-based therapy. Int J Mol Sci. 2019a;20(17):4130.
Balestra D, Maestri I, Branchini A, Ferrarese M, Bernardi F, Pinotti M. An altered splicing registry explains the differential ExSpeU1-mediated rescue of splicing mutations causing haemophilia A. Front Genet. 2019b;10:974.
Balestra D, Ferrarese M, Lombardi S, Ziliotto N, Branchini A, Petersen N, et al. An exon-specific small nuclear U1 RNA (ExSpeU1) improves hepatic OTC expression in a splicing-defective spf/ash mouse model of ornithine transcarbamylase deficiency. Int J Mol Sci. 2020a;21(22):8735.
Balestra D, Scalet D, Ferrarese M, Lombardi S, Ziliotto N, Croes CC, et al. A compensatory U1snRNA partially rescues FAH splicing and protein expression in a splicing-defective mouse model of tyrosinemia type I. Int J Mol Sci. 2020b;21(6):2136.
Barbosa-Morais NL, Irimia M, Pan Q, Xiong HY, Gueroussov S, Lee LJ, et al. The evolutionary landscape of alternative splicing in vertebrate species. Science. 2012;338(6114):1587–93.
Bochner R, Ziv Y, Zeevi D, Donyo M, Abraham L, Ashery-Padan R, et al. Phosphatidylserine increases IKBKAP levels in a humanized knock-in IKBKAP mouse model. Hum Mol Genet. 2013;22(14):2785–94.
Brown SC, Fernandez-Fuente M, Muntoni F, Vissing J. Phenotypic spectrum of α-dystroglycanopathies associated with the c.919T>a variant in the FKRP gene in humans and mice. J Neuropathol Exp Neurol. 2020;79(12):1257–64.
Cunningham SC, Kok CY, Spinoulas A, Carpenter KH, Alexander IE. AAV-encoded OTC activity persisting to adulthood following delivery to newborn spfash mice is insufficient to prevent shRNA-induced hyperammonaemia. Gene Ther. 2013;20(12):1184–7.
Dal Mas A, Rogalska ME, Bussani E, Pagani F. Improvement of SMN2 pre-mRNA processing mediated by exon-specific U1 small nuclear RNA. Am J Hum Genet. 2015;96(1):93–103.
De Conti L, Baralle M, Buratti E. Exon and intron definition in pre-mRNA splicing. Wiley Interdiscip Rev RNA. 2013;4(1):49–60.
Donadon I, Pinotti M, Rajkowska K, Pianigiani G, Barbon E, Morini E, et al. Exon-specific U1 snRNAs improve ELP1 exon 20 definition and rescue ELP1 protein expression in a familial dysautonomia mouse model. Hum Mol Genet. 2018;27(14):2466–76.
Donadon I, Bussani E, Riccardi F, Licastro D, Romano G, Pianigiani G, et al. Rescue of spinal muscular atrophy mouse models with AAV9-exon-specific U1 snRNA. Nucleic Acids Res. 2019;47(14):7618–32.
Donegà S, Rogalska ME, Pianigiani G, Igreja S, Amaral MD, Pagani F. Rescue of common exon-skipping mutations in cystic fibrosis with modified U1 snRNAs. Hum Mutat. 2020;41(12):2143–54.
Elsea SH, Lucas RE. The mousetrap: what we can learn when the mouse model does not mimic the human disease. ILAR J. 2002;43(2):66–79.
Ferraresi P, Balestra D, Guittard C, Buthiau D, Pan-Petesh B, Maestri I, et al. Next-generation sequencing and recombinant expression characterized aberrant splicing mechanisms and provided correction strategies in factor VII deficiency. Haematologica. 2020;105(3):829–37. https://doi.org/10.3324/haematol.2019.217539.
Förch P, Puig O, Martínez C, Séraphin B, Valcárcel J. The splicing regulator TIA-1 interacts with U1-C to promote U1 snRNP recruitment to 5′ splice sites. EMBO J. 2002;21(24):6882–92.
Gal-Mark N, Schwartz S, Ram O, Eyras E, Ast G. The pivotal roles of TIA proteins in 5′ splice-site selection of Alu exons and across evolution. PLoS Genet. 2009;5(11):e1000717.
Glaus E, Schmid F, Da Costa R, Berger W, Neidhardt J. Gene therapeutic approach using mutation-adapted U1 snRNA to correct a RPGR Splice defect in patient-derived cells. Mol Ther. 2011;19(5):936–41.
Hartin SN, Means JC, Alaimo JT, Younger ST. Expediting rare disease diagnosis: a call to bridge the gap between clinical and functional genomics. Mol Med. 2020;26(1):117.
Hodges PE, Rosenberg LE. The spf(ash) mouse: a missense mutation in the ornithine transcarbamylase gene also causes aberrant mRNA splicing. Proc Natl Acad Sci USA. 1989;86(11):4142–6.
Kim E, Magen A, Ast G. Different levels of alternative splicing among eukaryotes. Nucleic Acids Res. 2007;35(1):125–31.
Lee B, Kim Y, Kim S, Goh S, Kim J, Oh S, et al. Modified U1 snRNA and antisense oligonucleotides rescue splice mutations in SLC26A4 that cause hereditary hearing loss. Hum Mutat. 2019. https://doi.org/10.1002/humu.23774.
Martín E, Vivori C, Rogalska M, Herrero-Vicente J, Valcárcel J. Alternative splicing regulation of cell-cycle genes by SPF45/SR140/CHERP complex controls cell proliferation. RNA. 2021;27(12):1557–76.
Martínez-Pizarro A, Dembic M, Pérez B, Andresen BS, Desviat LR. Intronic PAH gene mutations cause a splicing defect by a novel mechanism involving U1snRNP binding downstream of the 5′ splice site. PLoS Genet. 2018;14(4):1–17.
Merkin J, Russell C, Chen P, Burge CB. Evolutionary dynamics of gene and isoform regulation in mammalian tissues. Science. 2012;338(6114):1593–9.
Moscioni D, Morizono H, McCarter RJ, Stern A, Cabrera-Luque J, Hoang A, et al. Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors. Mol Ther. 2006;14(1):25–33.
Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature. 2010;463(7280):457–63.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.
Rivera-Barahona A, Sánchez-Alcudia R, Viecelli HM, Rüfenacht V, Pérez B, Ugarte M, et al. Functional characterization of the spf/ash splicing variation in OTC deficiency of mice and man. PLoS ONE. 2015;10(4):e0122966–e0122966.
Rogalska ME, Tajnik M, Licastro D, Bussani E, Camparini L, Mattioli C, et al. Therapeutic activity of modified U1 core spliceosomal particles. Nat Commun. 2016;7(1):1–13.
Scalet D, Balestra D, Rohban S, Bovolenta M, Perrone D, Bernardi F, et al. Exploring splicing-switching molecules for Seckel syndrome therapy. Biochim Biophys Acta. 2017;1863(1):15–20.
Scalet D, Sacchetto C, Bernardi F, Pinotti M, Van De Graaf SFJ, Balestra D. The somatic FAH C.1061C>A change counteracts the frequent FAH c.1062+5G>A mutation and permits U1snRNA-based splicing correction. J Hum Genet. 2018;63(5):683–6.
Scalet D, Maestri I, Branchini A, Bernardi F, Pinotti M, Balestra D. Disease-causing variants of the conserved +2T of 5′ splice sites can be rescued by engineered U1snRNAs. Hum Mutat. 2019;40(1):48–52.
Schmid F, Hiller T, Korner G, Glaus E, Berger W, Neidhardt J. A gene therapeutic approach to correct splice defects with modified U1 and U6 snRNPs. Hum Gene Ther. 2013;24(1):97–104.
Tan J, Ho JXJ, Zhong Z, Luo S, Chen G, Roca X. Noncanonical registers and base pairs in human 5′ splice-site selection. Nucleic Acids Res. 2016;44(8):3908–21.
Taneri B, Asilmaz E, Gaasterland T. Biomedical impact of splicing mutations revealed through exome sequencing. Mol Med. 2012;18(2):314–9.
Telias M. Fragile X syndrome pre-clinical research: comparing mouse- and human-based models. Methods Mol Biol Clifton NJ. 2019;1942:155–62.
Tuchman M, Jaleel N, Morizono H, Sheehy L, Lynch MG. Mutations and polymorphisms in the human ornithine transcarbamylase gene. Hum Mutat. 2002;19(2):93–107.
Wang L, Wang H, Morizono H, Bell P, Jones D, Lin J, et al. Sustained correction of OTC deficiency in spfash mice using optimized self-complementary AAV2/8 vectors. Gene Ther. 2011;19(4):404–10.
Wang L, Morizono H, Lin J, Bell P, Jones D, McMenamin D, et al. Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome. Mol Genet Metab. 2012;105(2):203–11.
Wang I, Hennig J, Jagtap PKA, Sonntag M, Valcárcel J, Sattler M. Structure, dynamics and RNA binding of the multi-domain splicing factor TIA-1. Nucleic Acids Res. 2014;42(9):5949–66.
Yamaguchi S, Brailey LL, Morizono H, Bale AE, Tuchman M. Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene. Hum Mutat. 2006;27(7):626–32.
Yamazaki N, Kanazawa K, Kimura M, Ike H, Shinomiya M, Tanaka S, et al. Use of modified U1 small nuclear RNA for rescue from exon 7 skipping caused by 5′-splice site mutation of human cathepsin A gene. Gene. 2018;677:41–8.